Wilkins Investment Counsel’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$5.08M Buy
180,975
+1,620
+0.9% +$43.1K 0.73% 44
2025
Q4
$4.47M Sell
179,355
-20,005
-10% -$504K 0.65% 46
2025
Q3
$5.08M Sell
199,360
-2,850
-1% -$70.3K 0.72% 42
2025
Q2
$4.9M Sell
202,210
-3,376
-2% -$78.7K 0.69% 42
2025
Q1
$5.21M Sell
205,586
-53,100
-21% -$1.39M 0.75% 42
2024
Q4
$6.86M Sell
258,686
-5,248
-2% -$142K 0.99% 36
2024
Q3
$7.64M Buy
263,934
+2,700
+1% +$78.8K 1.06% 36
2024
Q2
$7.31M Buy
261,234
+4,183
+2% +$115K 1.09% 36
2024
Q1
$7.13M Buy
257,051
+153,890
+149% +$4.27M 1.04% 35
2023
Q4
$2.97M Buy
103,161
+1,000
+1% +$30.2K 0.72% 40
2023
Q3
$3.39M Sell
102,161
-688
-0.7% -$24.3K 0.92% 37
2023
Q2
$3.77M Sell
102,849
-7,400
-7% -$288K 0.99% 37
2023
Q1
$4.5M Buy
110,249
+600
+0.5% +$25.9K 1.18% 35
2022
Q4
$5.62M Sell
109,649
-315
-0.3% -$15.1K 1.48% 33
2022
Q3
$4.81M Hold
109,964
1.41% 33
2022
Q2
$5.76M Sell
109,964
-2,500
-2% -$127K 1.53% 31
2022
Q1
$5.82M Sell
112,464
-1,307
-1% -$67.8K 1.31% 35
2021
Q4
$6.72M Sell
113,771
-1,000
-0.9% -$49.5K 1.48% 32
2021
Q3
$4.94M Hold
114,771
1.21% 36
2021
Q2
$4.49M Sell
114,771
-600
-0.5% -$23.3K 1.11% 34
2021
Q1
$4.18M Sell
115,371
-3,800
-3% -$135K 1.08% 32
2020
Q4
$4.39M Sell
119,171
-9,070
-7% -$333K 1.21% 32
2020
Q3
$4.46M Hold
128,241
1.33% 31
2020
Q2
$3.98M Sell
128,241
-422
-0.3% -$14.3K 1.26% 32
2020
Q1
$3.98M Sell
128,663
-2,233
-2% -$76.1K 1.45% 28
2019
Q4
$4.87M Hold
130,896
1.38% 29
2019
Q3
$4.46M Buy
130,896
+843
+0.6% +$30.7K 1.34% 30
2019
Q2
$5.34M Sell
130,053
-2,951
-2% -$117K 1.6% 28
2019
Q1
$5.36M Sell
133,004
-5,270
-4% -$211K 1.62% 27
2018
Q4
$5.73M Sell
138,274
-106
-0.1% -$4.4K 1.9% 23
2018
Q3
$5.79M Sell
138,380
-3,056
-2% -$118K 1.73% 27
2018
Q2
$4.87M Sell
141,436
-57,993
-29% -$1.98M 1.53% 27
2018
Q1
$6.71M Sell
199,429
-78,947
-28% -$2.71M 2.12% 22
2017
Q4
$9.57M Sell
278,376
-8,356
-3% -$285K 2.86% 13
2017
Q3
$9.71M Sell
286,732
-371
-0.1% -$11.9K 2.95% 13
2017
Q2
$9.15M Sell
287,103
-1,354
-0.5% -$42.7K 2.91% 12
2017
Q1
$9.36M Buy
288,457
+4,854
+2% +$153K 3% 11
2016
Q4
$8.74M Buy
283,603
+12,226
+5% +$373K 2.79% 14
2016
Q3
$8.72M Buy
271,377
+2,249
+0.8% +$75.2K 2.93% 11
2016
Q2
$8.99M Buy
269,128
+2,108
+0.8% +$67.3K 3.04% 9
2016
Q1
$7.51M Buy
267,020
+18,329
+7% +$524K 2.75% 14
2015
Q4
$7.62M Sell
248,691
-10,435
-4% -$328K 2.86% 12
2015
Q3
$7.72M Sell
259,126
-211
-0.1% -$6.76K 2.95% 9
2015
Q2
$8.25M Sell
259,337
-1,475
-0.6% -$48.1K 3.01% 9
2015
Q1
$8.61M Sell
260,812
-182
-0.1% -$5.79K 3.04% 7
2014
Q4
$7.71M Sell
260,994
-2,826
-1% -$81K 2.68% 13
2014
Q3
$7.4M Sell
263,820
-633
-0.2% -$17.8K 2.64% 14
2014
Q2
$7.45M Sell
264,453
-18,577
-7% -$530K 2.63% 15
2014
Q1
$8.63M Buy
283,030
+224
+0.1% +$6.68K 3.18% 4
2013
Q4
$8.22M Buy
282,806
+14,161
+5% +$412K 3.41% 6
2013
Q3
$7.32M Sell
268,645
-4,877
-2% -$133K 3.34% 7
2013
Q2
$7.27M Buy
+273,522
New +$7.56M 3.37% 6

Other funds holding PFE

Wilkins Investment Counsel's PFE Position: Q1 2026 in Review

Wilkins Investment Counsel increased its Pfizer (PFE) stake by 0.9% in Q1 2026, buying an estimated $43.1K and bringing the position to 180,975 shares worth $5.08M. The position accounts for 0.73% of the portfolio, ranked #44.

Wilkins Investment Counsel first reported a position in PFE in Q2 2013 and has held it in 52 quarters since. The position peaked at $9.71M in Q3 2017. 2,939 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Wilkins Investment Counsel held 180,975 shares of Pfizer worth $5.08M as of Q1 2026.
  • Wilkins Investment Counsel bought 1,620 Pfizer shares in Q1 2026, an estimated $43.1K.
  • Pfizer made up 0.73% of Wilkins Investment Counsel's portfolio in Q1 2026, its #44 holding.
  • Wilkins Investment Counsel first reported a position in Pfizer in Q2 2013 and has held it in 52 quarters since.
  • Wilkins Investment Counsel's Pfizer position peaked at $9.71M in Q3 2017.
  • 2,939 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Wilkins Investment Counsel's 13F filing for Q1 2026, filed 7 May 2026.